Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 12th, 2021

Costantino Iadecola, MD, is awarded the AHA’s 2021 Basic Research Prize


Costantino Iadecola, MD, FAHA
Costantino Iadecola, MD, FAHA

Costantino Iadecola, MD, FAHA, of Weill Cornell Medicine in New York City, was recognized for his outstanding work in cerebrovascular biology, particularly in the areas of stroke and dementia, with the 2021 Basic Research Award.

Dr. Iadecola is a board-certified neurologist whose research focuses on ischemic brain injury, neurodegeneration and cognitive impairment. He is the director and chair of the Feil Family Brain and Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medicine in New York City. 

Dr. Iadecola is recognized to have pioneered and validated the concept of the neurovascular unit, a widely accepted notion that neurons and cerebrovascular cells work together to maintain the health of the brain. This concept inspired new research on mechanisms that regulate cerebral perfusion and on how their failure causes brain diseases. His discovery of the cerebrovascular effects of the amyloid-beta peptide and tau established that neurovascular dysfunction is an early biomarker for Alzheimer’s disease. His research demonstrates a relationship between innate immunity and the deleterious effects of hypertension on neurovascular regulation and cognitive function and found that high-salt diets cause dementia through the Alzheimer protein tau, bridging the age-old gap between neurovascular and neurodegenerative diseases. Dr. Iadecola’s work also details how microbiota of the gut can influence a patient’s susceptibility to ischemic stroke. 

“I am honored to receive the Basic Research Prize, which I humbly accept on behalf of my mentors, colleagues and collaborators,” said Dr. Iadecola. “I am grateful to the American Heart Association for the continued support I received since the very beginning of my clinician-scientist career.”  

Dr. Iadecola earned his medical degree from the University of Rome, Italy. He first came to the United States in the 1980s as a post-doctoral fellow in neurobiology at Weill Cornell Medicine in New York. After completing a neurology residency at New York-Presbyterian/Weill Cornell Medical Center in 1990, he joined the University of Minnesota Medical School as an assistant professor in neurology before returning to New York City as a professor of neurology and neuroscience at Weill Cornell Medicine, where he has been for the past 20 years.  

His work has earned accolades from the AHA, the American Academy of Neurology, the National Institutes of Health and the Alzheimer’s Association. He was previously recognized by the association with its 2009 Willis Lecture Award, given in recognition of his contributions to the role of prostaglandins and nitric oxide in stroke damage and to the role of cerebral blood vessel dysfunction in Alzheimer's disease. He won the 2015 Excellence Award in Hypertension Research from the association in recognition of his research connecting hypertension and Alzheimer’s disease. He was honored again by the association with a 2019 Distinguished Scientist Award to recognize his research contributions to cardiovascular disease, stroke and dementia. Additionally, in 2011, the Alzheimer’s Association recognized Dr. Iadecola with the Zenith Fellow Award, which is prestigious worldwide recognition in Alzheimer’s research.  

His research has been documented in nearly 400 papers published in peer-reviewed journals, and he is listed by Clarivate Analytics as one of most highly cited researcher in the world in his field.

 

Interesting Stories
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
More Content
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021